Michelle M Dolan

Medicine & Life Sciences

1. Cytogenetics 100%
2. Fluorescence In Situ Hybridization 82%
3. Cell Transplantation 62%
4. Allogeneic Cells 59%
5. Chromosome Aberrations 57%
6. Myelodysplastic Syndromes 47%
7. Cytogenetic Analysis 46%
8. Karyotype 45%
9. Bone Marrow 44%
10. Precursor Cell Lymphoblastic Leukemia-Lymphoma 42%
11. Acute Myeloid Leukemia 40%
12. Comparative Genomic Hybridization 39%
13. Leukemia 34%
14. Pathologists 33%
15. Lymphoma 29%
16. Genes 29%
17. Core Binding Factors 29%
18. Recurrence 26%
19. Neoplasms 26%
20. Transplants 26%
21. Gene Rearrangement 25%
22. Medical Genetics 24%
23. Survival 24%
24. Ewing's Sarcoma 24%
25. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24%
26. Stem Cell Transplantation 24%
27. Hematopoietic Stem Cell Transplantation 24%
28. Fragile X Syndrome 23%
29. human ERBB2 protein 23%
30. Acute Promyelocytic Leukemia 23%
31. Monosomy Chromosome 7 23%
32. Follicular Lymphoma 22%
33. Transplantation 19%
34. Pleomorphic Adenoma 19%
35. Confidence Intervals 18%
36. Tissue Donors 17%
37. Partial deletion Chromosome 11p 17%
38. Fetal Blood 17%
39. RNA-Binding Protein EWS 16%
40. Genetic Testing 16%
41. Wolman Disease 16%
42. Blast Crisis 16%
43. Intellectual Disability 15%
44. Hematopoietic Stem Cells 15%
45. Polymerase Chain Reaction 15%
46. HhAntag691 15%
47. Plasma Cell Neoplasms 14%
48. Typical Teratoid Rhabdoid Tumor 14%
49. Atypical Teratoid Tumor 14%